Victoza is a medicine used in addition to diet and exercise in adults and children from 10 years of age who have type 2 diabetes.
Victoza is used:
- on its own when use of metformin (another medicine for type 2 diabetes) is not recommended;
- as an ‘add-on’ to other diabetes medicines.
Victoza contains the active substance liraglutide.
Victoza : EPAR - Medicine overview (PDF/140.31 KB)
First published: 08/07/2009
Last updated: 29/04/2021
Victoza : EPAR - Risk-management-plan summary (PDF/79.65 KB)
First published: 15/10/2019
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
Diabetes Mellitus, Type 2
|Anatomical therapeutic chemical (ATC) code||
Novo Nordisk A/S
|Date of issue of marketing authorisation valid throughout the European Union||
24/09/2020 Victoza - EMEA/H/C/001026 - PSUSA/00001892/201912
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Drugs used in diabetes
Victoza is indicated for the treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
- in addition to other medicinal products for the treatment of diabetes.
For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied.
European Medicines Agency investigates findings on pancreatic risks with GLP-1-based therapies for type-2 diabetes26/03/2013
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 September 201123/09/2011